Skip to main content

Vomiting

9
Pipeline Programs
7
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
6
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 14 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Monarch Therapeutics
Monarch TherapeuticsPA - Philadelphia
1 program
1
TopiramatePhase 41 trial
Active Trials
NCT00286988Terminated12Est. Jun 2007
ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
2
1
CasopitantPhase 3
CasopitantPhase 1
GW679769Phase 1
HEC or MECN/A
MSD
MSDIreland - Ballydine
3 programs
2
RotaTeq™ - Rotavirus Vaccine, Live, Oral, PentavalentPhase 3Vaccine1 trial
aprepitantPhase 31 trial
Functional Living Index - EmesisN/A1 trial
Active Trials
NCT00696280Completed106Est. Nov 2009
NCT00362648Completed7,504Est. Mar 2009
NCT00080444Completed50Est. Mar 2007
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
2
RotaTeq™ - Rotavirus Vaccine, Live, Oral, PentavalentPhase 3Vaccine
aprepitantPhase 3
Functional Living Index - EmesisN/A
Astellas
AstellasChina - Shenyang
1 program
1
RamosetronPhase 31 trial
Active Trials
NCT00272285Completed287Est. Mar 2008
GSK
GSKLONDON, United Kingdom
3 programs
HEC or MECN/A1 trial
CasopitantPHASE_11 trial
GW679769PHASE_11 trial
Active Trials
NCT01366599Completed12,058Est. Jul 2009
NCT00358813Completed18Est. Aug 2008
NCT00359177Completed24Est. Oct 2006
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Functional Living Index - EmesisN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Monarch TherapeuticsTopiramate
MSDRotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent
AstellasRamosetron
MSDaprepitant
GSKCasopitant
GSKGW679769
GSKHEC or MEC
MSDFunctional Living Index - Emesis

Clinical Trials (8)

Total enrollment: 20,059 patients across 8 trials

NCT00286988Monarch TherapeuticsTopiramate

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Start: Mar 2006Est. completion: Jun 200712 patients
Phase 4Terminated
NCT00362648MSDRotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent

Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

Start: Mar 2007Est. completion: Mar 20097,504 patients
Phase 3Completed
NCT00272285AstellasRamosetron

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Start: Jan 2006Est. completion: Mar 2008287 patients
Phase 3Completed
NCT00080444MSDaprepitant

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Start: Apr 2004Est. completion: Mar 200750 patients
Phase 3Completed
NCT00358813GSKCasopitant

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

Start: Sep 2006Est. completion: Aug 200818 patients
Phase 1Completed
NCT00359177GSKGW679769

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

Start: Dec 2005Est. completion: Oct 200624 patients
Phase 1Completed
NCT01366599GSKHEC or MEC

CV Events in Emetogenic Chemotherapy

Start: May 2009Est. completion: Jul 200912,058 patients
N/ACompleted
NCT00696280MSDFunctional Living Index - Emesis

Observational Study of Delayed Nausea and Vomiting

Start: Nov 2006Est. completion: Nov 2009106 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.